Activities of Hexadecylphosphocholine (miltefosine), AmBisome, and Sodium Stibogluconate (Pentostam) Against Leishmania Donovani in Immunodeficient Scid Mice

Overview

Journal Antimicrob Agents Chemother

Publisher American Society for Microbiology

Specialty Pharmacology

Date 2001 May 17

PMID 11353640

Citations 32

Authors

P Escobar

V Yardley

S L Croft

Affiliations

Soon will be listed here.

Abstract

In both scid and BALB/c mouse-Leishmania donovani models, hexadecyphosphocholine (miltefosine) and AmBisome had similar levels of activity. In contrast, sodium stibogluconate (Pentostam) was significantly less active against L. donovani in scid mice than in BALB/c mice. The in vitro anti-leishmanial activity of miltefosine was similar in peritoneal macrophages derived from both scid and BALB/c mice, whereas Pentostam and AmBisome were significantly more active in the latter.

Citing Articles

Protective Efficacy in a Hamster Model of a Multivalent Vaccine for Human Visceral Leishmaniasis (MuLeVaClin) Consisting of the KMP11, LEISH-F3+, and LJL143 Antigens in Virosomes, Plus GLA-SE Adjuvant.

Fernandez L, Solana J, Sanchez C, Jimenez M, Requena J, Coler R Microorganisms. 2021; 9(11).

PMID: 34835379 PMC: 8618729. DOI: 10.3390/microorganisms9112253.

Oral treatment with T6-loaded yeast cell wall particles reduces the parasitemia in murine visceral leishmaniasis model.

Scariot D, Volpato H, Fernandes N, Lazarin-Bidoia D, Borges O, Sousa M Sci Rep. 2019; 9(1):20080.

PMID: 31882925 PMC: 6934808. DOI: 10.1038/s41598-019-56647-w.

Preclinical candidate for the treatment of visceral leishmaniasis that acts through proteasome inhibition.

Wyllie S, Brand S, Thomas M, De Rycker M, Chung C, Pena I Proc Natl Acad Sci U S A. 2019; 116(19):9318-9323.

PMID: 30962368 PMC: 6511062. DOI: 10.1073/pnas.1820175116.

A chronic bioluminescent model of experimental visceral leishmaniasis for accelerating drug discovery.

Alvarez-Velilla R, Gutierrez-Corbo M, Punzon C, Perez-Pertejo M, Balana-Fouce R, Fresno M PLoS Negl Trop Dis. 2019; 13(2):e0007133.

PMID: 30763330 PMC: 6392311. DOI: 10.1371/journal.pntd.0007133.

Identification of GSK3186899/DDD853651 as a Preclinical Development Candidate for the Treatment of Visceral Leishmaniasis.

Thomas M, De Rycker M, Ajakane M, Albrecht S, Alvarez-Pedraglio A, Boesche M J Med Chem. 2018; 62(3):1180-1202.

PMID: 30570265 PMC: 6407917. DOI: 10.1021/acs.jmedchem.8b01218.

References

Breiser A, Kim D, Fleer E, Damenz W, Drube A, Berger M . Distribution and metabolism of hexadecylphosphocholine in mice. Lipids. 1987; 22(11):925-6. DOI: 10.1007/BF02535556. View

Croft S, Neal R, Pendergast W, Chan J . The activity of alkyl phosphorylcholines and related derivatives against Leishmania donovani. Biochem Pharmacol. 1987; 36(16):2633-6. DOI: 10.1016/0006-2952(87)90543-0. View

Murray H, Oca M, Granger A, Schreiber R . Requirement for T cells and effect of lymphokines in successful chemotherapy for an intracellular infection. Experimental visceral leishmaniasis. J Clin Invest. 1989; 83(4):1253-7. PMC: 303815. DOI: 10.1172/JCI114009. View

Unger C, Damenz W, Fleer E, Kim D, Breiser A, Hilgard P . Hexadecylphosphocholine, a new ether lipid analogue. Studies on the antineoplastic activity in vitro and in vivo. Acta Oncol. 1989; 28(2):213-7. DOI: 10.3109/02841868909111249. View

Murray H, Granger A, Mohanty S . Response to chemotherapy in experimental visceral leishmaniasis: T cell-dependent but interferon-gamma- and interleukin-2-independent. J Infect Dis. 1991; 163(3):622-4. DOI: 10.1093/infdis/163.3.622. View

Vehmeyer K, Scheurich P, Eibl H, Unger C . Hexadecylphosphocholine-mediated enhancement of T-cell responses to interleukin 2. Cell Immunol. 1991; 137(1):232-8. DOI: 10.1016/0008-8749(91)90072-j. View

Hochhuth C, Vehmeyer K, Eibl H, Unger C . Hexadecylphosphocholine induces interferon-gamma secretion and expression of GM-CSF mRNA in human mononuclear cells. Cell Immunol. 1992; 141(1):161-8. DOI: 10.1016/0008-8749(92)90135-c. View

Kuhlencord A, Maniera T, Eibl H, Unger C . Hexadecylphosphocholine: oral treatment of visceral leishmaniasis in mice. Antimicrob Agents Chemother. 1992; 36(8):1630-4. PMC: 192021. DOI: 10.1128/AAC.36.8.1630. View

Murray H, Hariprashad J, Fichtl R . Treatment of experimental visceral leishmaniasis in a T-cell-deficient host: response to amphotericin B and pentamidine. Antimicrob Agents Chemother. 1993; 37(7):1504-5. PMC: 188002. DOI: 10.1128/AAC.37.7.1504. View

10.

Pronk L, Planting A, Oosterom R, Drogendijk T, Stoter G, Verweij J . Increases in leucocyte and platelet counts induced by the alkyl phospholipid hexadecylphosphocholine. Eur J Cancer. 1994; 30A(7):1019-22. DOI: 10.1016/0959-8049(94)90135-x. View

11.

Ibrahim M, Hag-Ali M, El-Hassan A, Theander T, Kharazmi A . Leishmania resistant to sodium stibogluconate: drug-associated macrophage-dependent killing. Parasitol Res. 1994; 80(7):569-74. DOI: 10.1007/BF00933004. View

12.

Zeisig R, Rudolf M, Eue I, Arndt D . Influence of hexadecylphosphocholine on the release of tumor necrosis factor and nitroxide from peritoneal macrophages in vitro. J Cancer Res Clin Oncol. 1995; 121(2):69-75. DOI: 10.1007/BF01202215. View

13.

Eue I, Zeisig R, Arndt D . Alkylphosphocholine-induced production of nitric oxide and tumor necrosis factor alpha by U 937 cells. J Cancer Res Clin Oncol. 1995; 121(6):350-6. DOI: 10.1007/BF01225687. View

14.

Engwerda C, Smelt S, Kaye P . An in vivo analysis of cytokine production during Leishmania donovani infection in scid mice. Exp Parasitol. 1996; 84(2):195-202. DOI: 10.1006/expr.1996.0105. View

15.

Croft S, Snowdon D, Yardley V . The activities of four anticancer alkyllysophospholipids against Leishmania donovani, Trypanosoma cruzi and Trypanosoma brucei. J Antimicrob Chemother. 1996; 38(6):1041-7. DOI: 10.1093/jac/38.6.1041. View

16.

Safa O, Parkin S, Matthew A, Bibby M . Morphological and immunological observations on the effects of hexadecylphosphocholine (HPC) in nude mice bearing MT-1 breast cancer xenografts. Anticancer Res. 1997; 17(1A):37-43. View

17.

Alvar J, Canavate C, Jimenez M, Laguna F, Lopez-Velez R, Molina R . Leishmania and human immunodeficiency virus coinfection: the first 10 years. Clin Microbiol Rev. 1997; 10(2):298-319. PMC: 172921. DOI: 10.1128/CMR.10.2.298. View

18.

Berman J . Human leishmaniasis: clinical, diagnostic, and chemotherapeutic developments in the last 10 years. Clin Infect Dis. 1997; 24(4):684-703. DOI: 10.1093/clind/24.4.684. View

19.

Arthur G, Bittman R . The inhibition of cell signaling pathways by antitumor ether lipids. Biochim Biophys Acta. 1998; 1390(1):85-102. DOI: 10.1016/s0005-2760(97)00163-x. View

20.

Le Fichoux Y, Rousseau D, Ferrua B, Ruette S, Lelievre A, Grousson D . Short- and long-term efficacy of hexadecylphosphocholine against established Leishmania infantum infection in BALB/c mice. Antimicrob Agents Chemother. 1998; 42(3):654-8. PMC: 105513. DOI: 10.1128/AAC.42.3.654. View